BioSpectrum
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

Agilus Diagnostics installs Illumina NovaSeq X to revolutionise genomic testing in India

28 January 2026 | News

NovaSeq X strengthens Agilus Diagnosticsâ?? molecular testing capabilities



Agilus Diagnostics, a subsidiary of Fortis Healthcare, has announced the installation of the Illumina NovaSeq X at its Mumbai reference laboratory—strengthening India's capacity for nextâ??generation sequencing at scale.

The launch was attended by Dr Ashutosh Raghuvanshi, MD & CEO, Fortis Healthcare; Dr Anand K., Managing Director & CEO, Agilus Diagnostics, and Deepak Narang, Chief Operating Officer, Agilus Diagnostics.

The NovaSeq X strengthens Agilus Diagnostics' molecular testing capabilities through highâ??throughput sequencing and scalable analytics. Its multiâ??omic capacity delivers rapid, highâ??resolution results across diverse clinical needs. Through Agilus' nationwide network, these advanced capabilities become accessible to clinicians and patients in both metro and emerging markets.

Powered by highâ??density flow cells and automation, the NovaSeq X enables whole exome sequencing (WES), whole genome sequencing (WGS), and multiâ??omic analysis with exceptional speed and accuracy. Deployed for highâ??fidelity clinical decisionâ??making—not just research—it provides physicians with actionable molecular insights and faster turnaround times.

Dr Ashutosh Raghuvanshi, MD & CEO, Fortis Healthcare, said, "Integrating advanced platforms like the Illumina NovaSeq X into clinical diagnostics is a pivotal step for India's healthcare ecosystem. Highâ??quality molecular insights are vital not only for oncology but also for diagnosing rare diseases, guiding targeted therapies, and advancing personalized and preventive care. Agilus' investment brings cuttingâ??edge science closer to patients and equips clinicians with actionable information to improve outcomes across a broad spectrum of conditions."

For clinicians and researchers, the enhanced capacity translates into:

- Whole exome and whole genome testing for comprehensive variant detection
- Genetic evaluation of inherited and rare disorders
- Reproductive and maternal health applications, including carrier screening and prenatal testing
- Pharmacogenomic assessments to inform drug response and dosing
- Infectious disease sequencing for pathogen tracking and antimicrobial resistance insights
- Liquid biopsy (ctDNA) analysis and multiâ??omic studies for longitudinal disease monitoring and deeper biological understanding